AMEX · APUS
Healthcare · Drug Manufacturers - Specialty & Generic
$1.64
Down-$0.45 (-21.53%)
Updated Sep 16, 2026, 11:06 AM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
APUS closed at $1.64 after 20 trading sessions, down 59.00% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $2.11 | $2.1101 | $1.60 | $1.64 | 66.3K |
| Sep 14, 2026 | $2.39 | $2.39 | $2.025 | $2.09 | 29.82K |
| Sep 11, 2026 | $2.16 | $2.26 | $2.09 | $2.105 | 20.69K |
| Sep 10, 2026 | $2.26 | $2.47 | $2.12 | $2.17 | 41.16K |
| Sep 9, 2026 | $2.30 | $2.35 | $2.17 | $2.29 | 29.57K |
| Sep 8, 2026 | $2.40 | $2.405 | $2.25 | $2.30 | 17.42K |
| Sep 4, 2026 | $2.49 | $2.60 | $2.42 | $2.42 | 24.39K |
| Sep 3, 2026 | $2.66 | $2.71 | $2.40 | $2.51 | 50.66K |
| Sep 2, 2026 | $3.17 | $3.38 | $2.5101 | $2.63 | 85.51K |
| Sep 1, 2026 | $3.87 | $3.87 | $3.41 | $3.54 | 29.31K |
| Aug 31, 2026 | $4.09 | $4.09 | $3.73 | $3.88 | 8.25K |
| Aug 28, 2026 | $4.10 | $4.10 | $3.861 | $3.87 | 9.07K |
| Aug 27, 2026 | $4.63 | $4.81 | $3.7366 | $3.95 | 172.41K |
| Aug 26, 2026 | $4.74 | $4.99 | $4.358 | $4.60 | 230.14K |
| Aug 25, 2026 | $4.78 | $5.35 | $4.65 | $4.97 | 49.12K |
| Aug 24, 2026 | $4.34 | $4.75 | $4.34 | $4.75 | 15.93K |
| Aug 21, 2026 | $4.30 | $5.43 | $4.175 | $4.84 | 559.64K |
| Aug 20, 2026 | $4.23 | $4.50 | $4.0911 | $4.39 | 17.21K |
| Aug 19, 2026 | $3.88 | $4.55 | $3.69 | $4.39 | 23.44K |
| Aug 18, 2026 | $3.99 | $4.30 | $3.85 | $4.00 | 38.21K |
The latest Smart Investors Daily articles mentioning APUS.
APUS research
Company profile and research snapshot.
Apimeds Pharmaceuticals Us Inc is a clinical-stage company. It is engaged in a pharmaceutical business that provides the biological drug Apitox to clients in the biological drug commercial transaction area. It are a clinical stage biopharmaceutical company in the process of developing Apitox, an intradermally administered bee venom-based toxin. Company focus is on developing therapies that address inflammation and pain management symptoms associated with knee OA and, to a lesser extent, MS. Apitox is currently marketed and sold by Apimeds Inc. in South Korea as Apitoxin for the treatment of OA.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Aug 21, 2026
-SEC Filing
Benzinga · Aug 18, 2026
Gainers Amylyx Pharmaceuticals (NASDAQ:AMLX) stock increased by 27.5% to $27.32 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.3 billion. bioAffinity Technologies
ChartMill · Jun 11, 2026
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Yahoo · Feb 11, 2026
MATAWAN, N.J. & LA JOLLA, Calif., February 11, 2026--Apimeds Pharmaceuticals US, Inc. and Lōkahi Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Addiction Medicine and Pain Medicine (DAAP) has confirmed a Type C meeting to discuss LT-100 (Apitox), a non-opioid biologic candidate being developed for the treatment of the signs and symptoms of osteoarthritis (OA). The meeting will be conducted via teleconference on Monday, May 4, 2026.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning APUS.
No results
No recent SID articles mention APUS.
